- Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression2016 | Faculty of Medicine in Hradec Králové
- Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma2016 | First Faculty of Medicine
- Extracorporeal elimination of circulating pegylated liposomal doxorubicin (PLD) to enhance the benefit of cytostatic therapy in platinum-resistant ovarian cancer patients2015 | Faculty of Medicine in Hradec Králové
- Liposomal doxorubicin in the treatment of breast cancer2008 | First Faculty of Medicine
- Liposomal doxorubicin in the treatment of breast cancer2008 | Publication without faculty affiliation
- Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer2020 | Faculty of Medicine in Hradec Králové
- Research Report University Hospital clinical trial EC-FV-06Publication without faculty affiliation
- Liposomal Doxorubicin Combined with Regional Hyperthermia: reducing Systemic Toxicity and Improving Locoregional Efficacy in the treatment of Solid Tumors2004 | Faculty of Medicine in Hradec Králové
- Pegylated Liposomal Doxorubicin in Combination With Hyperthermia in the Treatment of a Case of Advanced Hepatocellular Carcinoma2002 | Faculty of Medicine in Hradec Králové
- Pegylated Liposomal Doxorubicin in Combination with Hyperthermia for Treatment of Skin Metastases of Breast Carcinoma: A Case Report2001 | Faculty of Medicine in Hradec Králové
- Anthracyclines in the treatment of generalized breast cancer2011 | First Faculty of Medicine
- Extracorporeal apheresis system - A nanoparticle drugs' elimination method to enhance the benefit of cytostatic therapy in cancer patients2016 | Faculty of Medicine in Hradec Králové
- Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression2007 | First Faculty of Medicine
- Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years2020 | Faculty of Medicine in Hradec Králové
- Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.2008 | First Faculty of Medicine
- Modern Imaging Techniques for Anthracycline Cytostatics - Review of the Literature2013 | Publication without faculty affiliation
- Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial2020 | First Faculty of Medicine
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial2015 | First Faculty of Medicine
- Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)2019 | Third Faculty of Medicine